BLN-481 / Beeline Medicines, BMS - LARVOL DELTA

Beeline Medicines…announced the closing of a $126.3 million Series A extension, bringing its total Series A financing round to $426.3 million. (GlobeNewswire) - "The proceeds from the upsized Series A will support the initiation of several clinical studies across the Company’s broad immunology portfolio, including planned pivotal development of its lead program, afimetoran, in lupus...The Company has commenced pivotal development preparations in lupus ahead of the expected Phase 2 readout of afimetoran in systemic lupus erythematosus in the second half of 2026...Over the next 12 months, the Company expects to initiate additional clinical trials across its pipeline, including for lomedeucitinib...and BLN-481 (formerly BMS-986481)."

Financing • P2 data • Pipeline update • Atopic Dermatitis • Immunology • Inflammation • Systemic Lupus Erythematosus

Beeline Medicines formally launched Wednesday with $300 million in series A financing and a ready-made pipeline of immunology assets in-licensed from Bristol Myers Squibb that it hopes will help reshape how autoimmune and inflammatory diseases are treated. (Firstwordpharma Press Release) - "Beeline's lead programme, afimetoran (BMS-986256), is a once-daily oral small molecule designed to inhibit toll-like receptors 7 and 8 (TLR7/8), components of the innate immune system linked to the aberrant activation seen in systemic lupus erythematosus...'we expect several additional clinical trials to start across our pipeline over the next 12 months.'...Beyond afimetoran, the pipeline also includes an IL-2-CD25 fusion protein dubbed BMS-986326...The company is also working on a once-daily oral TYK2 inhibitor called lomedeucitinib (BMS-986322)....Additionally, the pipeline includes two IND-stage biologics, BMS-986481 and BMS-986498..."

Financing • New trial • Atopic Dermatitis • Immunology • Psoriasis • Systemic Lupus Erythematosus